PARP1 and pancreatic ductal adenocarcinoma: Here, we demonstrate that, using 18F-olaparib, measurement of the distribution, uptake, and PARP binding of olaparib with PET imaging in mouse models of pancreatic ductal adenocarcinoma could be achieved.